Through our commitment to patients with unmet needs, we’re raising awareness about HER2-positive biliary tract cancer (BTC), an aggressive type of cancer often associated with a poor prognosis. As we continue to focus on those for whom we can have the greatest impact, HER2-positive cancers are one area we’re applying the science by investigating and developing innovative solutions for patients.

Our presence at SABCS 2023 marks a significant step forward for Jazz as our oncology pipeline continues to evolve to address new tumor types such as breast cancer. We’re excited to gather with leaders in the breast cancer community and share our research, including findings for our HER2-targeted bispecific antibody in HER2+ breast cancer, which reflects our continuous dedication to reshaping cancer care and addressing unmet needs. 

November is National Epilepsy Awareness Month – a milestone that allows us to pause and reflect on both the progress the community has made for people living with this condition and their continued unmet needs. This time of reflection is especially important for people diagnosed with rare forms of epilepsy, as well as their families and caregivers, who are continuing to search for improved therapeutic outcomes.

Recently, Mat Davis, PhD, vice president and head of data science, presented at the 2023 STAT Summit where he shared a key moment in his career when he learned the necessity of breaking down silos to fully embrace quantitative experts across the three avenues of drug development.

As World Heart Day approaches, we are reminded of people who live with complex sleep disorders and how we can adequately address their unique needs. Learn more about the importance of thinking holistically about narcolepsy and idiopathic hypersomnia patients’ health from Jazz’s Dr. Kelvin Tan and Dr. Logan Schneider of the Stanford University School of Medicine.

Jazz’s oncology efforts are focused on delivering innovation to improve patient care, quality of life, and advancing scientific understanding of cancers with high unmet needs like acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), which often affect children. To learn more about progress in the fight against these childhood blood cancers, Jazz’s Abizer Gaslightwala spoke with pediatric hematologist/oncologist Dr. Rachel Rau.